Celmatix Announces Fertilome, the World’s First Comprehensive Screen for Genetic Factors Associated with Reproductive Conditions in Women

Test provides deeper insights into a woman’s reproductive health
profile to enable more proactive management of fertility

NEW YORK–(BUSINESS WIRE)–Celmatix, a next-generation women’s health company, today announced
Fertilome, a first-of-its-kind genetic screen that reveals how a woman’s
DNA may influence her reproductive health. The test, which is available
through physicians, gives women unique genetic insights, allowing them
to proactively manage their reproductive health and long-term fertility

Fertilome is the result of nearly eight years of Celmatix research
focused on the genetic factors associated with the most common
reproductive conditions that can lead to fertility difficulties in
women, including endometriosis, polycystic ovarian syndrome (PCOS), and
primary ovarian insufficiency—a precursor to early menopause. Age is
currently the primary fertility-related risk factor that many women
weigh when deciding when to start a family and whether to freeze eggs.
It is also one of the main factors cited when women are counseled about
their chances of success with fertility treatments. Fertilome will
reveal to women who are experiencing reproductive difficulties or who
plan to start or expand their families in their 30s or 40s if they carry
markers associated with common reproductive difficulties. This
information may allow them to make proactive decisions while they still
have time to act.

Over the last decade we have seen how genetic information has
transformed the cancer field. Providing individuals with deeper insight
into their health through genetics has impacted lifestyle choices,
prevention, and treatment decisions,” explained Dr. Piraye Yurttas Beim,
Celmatix founder and CEO. “Celmatix was founded to bring the same kind
of transformational change to the field of reproductive medicine, and it
is tremendously rewarding to see our nearly eight years of work bear
fruit through Fertilome. Women can now make potentially life-defining
decisions about how to proactively plan for the family they want to
build and be more efficient in overcoming fertility difficulties they
are experiencing using better, more personal information than age.”

OB-GYNs see women each day who are trying to conceive, sometimes after
just a few weeks, or months, but other times longer,” stated Dr. Aaron
Caughey, MD, Chair of Obstetrics and Gynecology and Associate Dean for
Women’s Health Research and Policy at Oregon Health & Science
University. “However, there hasn’t been a tool for physicians to use to
better understand and to guide patients who may be more likely to
encounter difficulty conceiving and need to seek the help of a
specialist earlier, or to counsel women who want to have children in the
future and may need to consider egg freezing to preserve optionality. A
test like Fertilome allows OB-GYNs to have these conversations with our
patients, helps patients to understand what their own genetic signature
might say about their fertility potential, and allows them to take
charge of their reproductive health.”

I’m always in search of tools to better understand the challenges my
infertility patients are facing that may not be evident with existing
tests,” explained Dr. Amber Cooper, MD, Medical and IVF Practice
Director at Centers for Reproductive Medicine and Wellness. She
continued, “I’m thrilled that, with Fertilome, fertility specialists now
have genetic-level insight into what may be causing a particular patient
to be experiencing reproductive challenges. Genetic tests like this will
help drive the next generation of treatment plans and help us start to
focus on family building plans that consider future fertility potential
as well as trying to help a patient get to a healthy pregnancy in the
short term. This insight will also be tremendously helpful for women in
their 30s who are considering egg preservation.”

Fertilome, a laboratory developed test, is run by Celmatix Clinical
Laboratories and is the result of a multi-year, systematic literature
review and meta-analysis to identify genetic variants that are
significantly associated with the most common female reproductive
conditions. These associations meet guidelines established by the
Clinical Genome Gene-Disease Clinical Validity Classification Framework
and the American College of Medical Genetics and Genomics (ACMG) and
Association of Molecular Pathology (AMP).

About Celmatix

Celmatix is a next-generation women’s health company transforming
reproductive healthcare through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them with more
personalized information. The company’s research-driven products include
Fertilome, the world’s first comprehensive genetic screen that reveals
what a woman’s DNA says about her reproductive health, and Polaris, a
real-time predictive analytics platform in use at leading fertility
clinics across the U.S., which helps physicians optimize patient
outcomes and improve the patient experience. For more information, visit www.celmatix.com.

About Celmatix Clinical Laboratories

Celmatix Clinical Laboratories is a high-complexity clinical diagnostics
laboratory. It is CLIA-certified for compliance, NY State Department of
Health permitted for molecular genetics, and College of American
Pathologists (CAP) accredited.


for Celmatix
Rachel Petersen, 262-206-0627